Connect Biopharma is actively recruiting for Phase 2 Seabreeze STAT studies targeting acute asthma and COPD exacerbations, with topline data expected in 1H26. Simcere submitted an NDA for rademikibart to treat atopic dermatitis in China, while Connect completed the termination of its ADR program and listed shares on Nasdaq. Positive data presented at ERS 2025 supports rademikibart’s potential efficacy and safety in patients with type 2 inflammatory markers. The company aims to deliver topline data in 1H26 and advance rademikibart in China. Financial results for Q3 2025 show cash of $54.8 million, with funds projected to last into 2027. License and collaboration revenues were $16,000 and $64,000 for the three and nine months ended September 30, 2025, respectively. Research and development expenses were $11.1 million and $26.5 million for the same periods, with general and administrative expenses at $6.6 million and $16.1 million. Net loss for Q3 2025 was $17.2 million, or $0.31 per share. Rademikibart is a human monoclonal antibody targeting IL-4Rα, aiming to treat Th2 inflammatory diseases like atopic dermatitis, asthma, and COPD. Connect Biopharma is focused on transforming care for asthma and COPD with rademikibart, conducting clinical studies globally. The company has granted an exclusive license to Simcere in Greater China and is eligible for milestone payments up to $110 million. For more information visit www.connectbiopharma.com.

Read more at GlobeNewswire: Connect Biopharma Reports Third Quarter 2025 Financial